279 related articles for article (PubMed ID: 28817342)
1. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
[TBL] [Abstract][Full Text] [Related]
2. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes.
Johansen RF; Søndergaard E; Linnebjerg H; Garhyan P; Lam ECQ; Porksen N; Jacober SJ; Nielsen S
Diabetes Obes Metab; 2018 Feb; 20(2):419-426. PubMed ID: 28817248
[TBL] [Abstract][Full Text] [Related]
3. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus.
Porksen NK; Linnebjerg H; Lam ECQ; Garhyan P; Pachori A; Pratley RE; Smith SR
Diabetes Obes Metab; 2018 May; 20(5):1193-1201. PubMed ID: 29316143
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3.
Bergenstal RM; Lunt H; Franek E; Travert F; Mou J; Qu Y; Antalis CJ; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
Diabetes Obes Metab; 2016 Nov; 18(11):1081-1088. PubMed ID: 27265390
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1.
Garg S; Dreyer M; Jinnouchi H; Mou J; Qu Y; Hartman ML; Rosilio M; Jacober SJ; Bastyr EJ;
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():25-33. PubMed ID: 27393697
[TBL] [Abstract][Full Text] [Related]
6. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.
Blevins T; Pieber TR; Colón Vega G; Zhang S; Bastyr EJ; Chang AM;
Diabetes Obes Metab; 2016 Nov; 18(11):1072-1080. PubMed ID: 27234693
[TBL] [Abstract][Full Text] [Related]
8. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
Mudaliar S; Henry RR; Ciaraldi TP; Armstrong DA; Burke PM; Pettus JH; Garhyan P; Choi SL; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen NK; Sinha VP; Linnebjerg H; Jacober SJ
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():17-24. PubMed ID: 27723226
[TBL] [Abstract][Full Text] [Related]
9. Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
Porksen N; Linnebjerg H; Garhyan P; Lam EC; Knadler MP; Jacober SJ; Hoevelmann U; Plum-Moerschel L; Watkins E; Gastaldelli A; Heise T
Diabetes Obes Metab; 2017 Apr; 19(4):482-488. PubMed ID: 27888561
[TBL] [Abstract][Full Text] [Related]
10. Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
Rosenstock J; Marre M; Qu Y; Zhang S; Bastyr EJ; Prince MJ; Chang AM
Diabetes Obes Metab; 2016 Nov; 18(11):1093-1097. PubMed ID: 27484021
[TBL] [Abstract][Full Text] [Related]
11. Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.
Jacober SJ; Prince MJ; Beals JM; Hartman ML; Qu Y; Linnebjerg H; Garhyan P; Haupt A
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():3-16. PubMed ID: 27723228
[TBL] [Abstract][Full Text] [Related]
12. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
[TBL] [Abstract][Full Text] [Related]
13. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial.
Morrow LA; Hompesch M; Jacober SJ; Leng Choi S; Qu Y; Sinha VP
Diabetes Obes Metab; 2016 Nov; 18(11):1065-1071. PubMed ID: 27169522
[TBL] [Abstract][Full Text] [Related]
14. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
Cusi K; Sanyal AJ; Zhang S; Hoogwerf BJ; Chang AM; Jacober SJ; Bue-Valleskey JM; Higdon AN; Bastyr EJ; Haupt A; Hartman ML
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():50-58. PubMed ID: 27723227
[TBL] [Abstract][Full Text] [Related]
15. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
Buse JB; Rodbard HW; Trescoli Serrano C; Luo J; Ivanyi T; Bue-Valleskey J; Hartman ML; Carey MA; Chang AM;
Diabetes Care; 2016 Jan; 39(1):92-100. PubMed ID: 26577417
[TBL] [Abstract][Full Text] [Related]
16. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
Ginsberg H; Cariou B; Orchard T; Chen L; Luo J; Bastyr EJ; Bue-Valleskey J; Chang AM; Ivanyi T; Jacober SJ; Hoogwerf BJ
Diabetes Obes Metab; 2016 Nov; 18(11):1089-1092. PubMed ID: 27486125
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial.
Grunberger G; Chen L; Rodriguez A; Tinahones FJ; Jacober SJ; Bue-Valleskey J;
Diabetes Obes Metab; 2016 Oct; 18 Suppl 2():34-42. PubMed ID: 27723225
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
[TBL] [Abstract][Full Text] [Related]
19. The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.
Pillai S; Duvvuru S; Bhatnagar P; Foster W; Farmen M; Shankar S; Harris C; Bastyr E; Hoogwerf B; Haupt A
Pharmacogenomics J; 2018 May; 18(3):487-493. PubMed ID: 29160303
[TBL] [Abstract][Full Text] [Related]
20. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Henry RR; Mudaliar S; Ciaraldi TP; Armstrong DA; Burke P; Pettus J; Garhyan P; Choi SL; Jacober SJ; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen N; Sinha VP; Linnebjerg H
Diabetes Care; 2014 Sep; 37(9):2609-15. PubMed ID: 24947791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
